Sp580
MEDICAL APPROACH TO DIFFUSE GASTRIC CANCER DIAGNOSIS, TREATMENT AND PREVENTION
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
The Funderburg Symposium focuses on fundamental and translational studies on the pathogenesis of gastric adenocarcinoma. This year's theme will focus on the genetics, surveillance and treatment for sporadic and hereditary diffuse gastric cancer.
The Funderburg Symposium focuses on fundamental and translational studies on the pathogenesis of gastric adenocarcinoma. This year's theme will focus on the genetics, surveillance and treatment for sporadic and hereditary diffuse gastric cancer.
Presenter
Tracks
Related Products
CLINICAL VALIDATION OF A CELL-FREE DNA BLOOD-BASED TEST FOR COLORECTAL CANCER SCREENING IN AN AVERAGE RISK POPULATION
BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
DISTINCT STOOL MICROBIOME METABOLIC SIGNATURE ASSOCIATED WITH VARYING COLONIC ADENOMA SUBTYPE
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…